Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.68 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078773 | 1.00 | NAPRT (0.68) | NAPRTPARP1MAPTHTTLMNA | |
| Hydrochloric Acid SCHEMBL5013375 | 0.98 | NAPRT (0.66) | NAPRTPARP1MAPTHTTLMNA | |
| Formic Acid SCHEMBL16670639 | 0.93 | NAPRT (0.59) | NAPRTPARP1MAPTHTTLMNA | |
| SCHEMBL27612856 | 0.83 | NAPRT (0.73) | NAPRTPARP1MAPTHTTLMNA | |
| SCHEMBL30475725 | 0.81 | NAPRT (0.59) | NAPRTPARP1MAPTHTTLMNA | |
| SCHEMBL310265 | 0.81 | NAPRT (0.70) | NAPRTPARP1MAPTHTTLMNA | |
| SCHEMBL29574424 | 0.81 | NAPRT (1.00) | NAPRTMAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL19280924 | 0.81 | NAPRT (1.00) | NAPRTMAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL28705950 | 0.81 | NAPRT (0.70) | NAPRTPARP1MAPTHTTLMNA | |
| SCHEMBL30901792 | 0.81 | NAPRT (0.70) | NAPRTPARP1MAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | HK INNO.N CORPORATION (KR) | 2024-12-31 | — | — | US | claimed |
| US-20220009902-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HK INNO.N CORPORATION (KR) | 2022-01-13 | — | — | US | claimed |
| EP-2635556-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | claimed |
| US-20130231351-A1 | SIR2 REGULATION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-09-05 | — | — | US | claimed |
| WO-2012061418-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | claimed |
| US-20110178102-A1 | SIR2 REGULATION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-07-21 | — | — | US | claimed |
| EP-1648459-A1 | SIR2 REGULATION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005016342-A1 | SIR2 REGULATION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2005-02-24 | — | — | WO | claimed |
| EP-1068187-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999051580-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 1999-10-14 | — | — | WO | claimed |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | ACTIO BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | disclosed |
| US-12582657-B2 | Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250375542-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | CANCER TARGETED TECH LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | NAPRT 213/4885PARP1 179/4885MAPT 4734/4885 |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | KCNT1, KCNT2, KCNJ2 | NAPRT 983/4885PARP1 2605/4885MAPT 4112/4885 |
| US-20130231351-A1 | SIR2 REGULATION | SIRT2, SIRT1, SIRT6 | NAPRT 296/4885PARP1 346/4885MAPT 3887/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | NAPRT 113/4885PARP1 1127/4885MAPT 4084/4885 |
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | MAP3K20, MAP3K1, MAP3K15 | NAPRT 3194/4885PARP1 1984/4885MAPT 992/4885 |
| US-12582657-B2 | Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | KRAS, NRAS, BRAF | NAPRT 2622/4885PARP1 108/4885MAPT 3576/4885 |
| US-12600696-B2 | Aromatic compounds | CCR1, CCRL2, AHR | NAPRT 4144/4885PARP1 1872/4885MAPT 4404/4885 |
| US-20110178102-A1 | SIR2 REGULATION | SIRT2, SIRT1, SIRT6 | NAPRT 296/4885PARP1 346/4885MAPT 3887/4885 |
| US-20220009902-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | MAP3K20, MAP3K1, MAP3K15 | NAPRT 2974/4885PARP1 1998/4885MAPT 938/4885 |
| US-20250375542-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | FOLH1, PSMA1, PSMA2 | NAPRT 1449/4885PARP1 1234/4885MAPT 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.